Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein Extracellular side |
Domain |
PF03160 Calx-beta domain PF00093 von Willebrand factor type C domain |
Function |
- |
Biological Process |
GO:0001655 urogenital system development GO:0001656 metanephros development GO:0001822 kidney development GO:0003338 metanephros morphogenesis GO:0030326 embryonic limb morphogenesis GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035113 embryonic appendage morphogenesis GO:0043588 skin development GO:0048736 appendage development GO:0060021 palate development GO:0060173 limb development GO:0060993 kidney morphogenesis GO:0072001 renal system development |
Molecular Function | - |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0044420 extracellular matrix component GO:0061618 sublamina densa |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FRAS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FRAS1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FRAS1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of FRAS1 in various data sets.
|
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FRAS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FRAS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FRAS1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FRAS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FRAS1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FRAS1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | FRAS1 |
Name | Fraser extracellular matrix complex subunit 1 |
Aliases | FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1 |
Chromosomal Location | 4q21.21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting FRAS1 collected from DrugBank database. |
There is no record. |